Multiple peer-reviewed articles have shown that the RMS is a validated and cost effective case-finding tool for bipolar I disorder. 

In its first validation study, McIntyre et al. (2021) found that a positive score (4 or higher) showed a sensitivity and specificity of 88% and 80%, respectively, while a borderline score (3 or higher) showed a sensitivity and specificity of 97% and 59%, respectively.

In a survey of 200 healthcare providers, Thase et al. (2023) found that the RMS is easy to administer and score. In total, 84% of healthcare providers reported that the RMS would have a positive impact on their practice and 76% said they would be likely to use the RMS to screen new patients with depressive symptoms.

The Daymark Foundation, BIT and the Aune Foundation completed a developmental evaluation of the RMS in two primary care practices to better understand its utility, enablers and barriers to successful implementation, and scaling considerations. These results are currently pending publication.